Showing 341 - 360 results of 16,585 for search '(( 50 we decrease ) OR ( 50 ((((ns decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 0.65s Refine Results
  1. 341
  2. 342

    Loss of cytoplasmic incompatibility in <i>Wolbachia</i>-infected <i>Aedes aegypti</i> under field conditions by Perran A. Ross (844275)

    Published 2019
    “…In a second experiment under somewhat hotter conditions (>40°C in 50% shade), field-reared <i>w</i>Mel-infected females had their egg hatch reduced to 25% when crossed to field-reared <i>w</i>Mel-infected males. …”
  3. 343

    Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

    Published 2021
    “…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”
  4. 344
  5. 345

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  6. 346

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  7. 347

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  8. 348

    DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  9. 349

    DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  10. 350

    DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  11. 351

    Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

    Published 2023
    “…The epidural anesthesia on the general anesthetic (GA) requirements has not been well investigated. Therefore, we conducted the present study to explore the predicted effect-site concentration of propofol (Ce<sub>prop</sub>) required for achieving the loss of consciousness (LOC) in 50% of patients (EC<sub>50</sub>) with or without epidural anesthesia.…”
  12. 352

    The decreasing rates of V<sub>p</sub> with temperature. by Nazlı Tunar Özcan (14833635)

    Published 2023
    “…The V<sub>p</sub> and the σ<sub>t</sub> of Çankırı rock salt decrease with increasing temperatures of samples whereas the σ<sub>c</sub> increases. …”
  13. 353
  14. 354
  15. 355

    S2 Fig - by Xinyue Yang (629144)

    Published 2024
    “…Sprague-Dawley (SD) rats were randomly divided into four groups: normal saline (NS), and 50 (50-cur), 100 (100-cur), and 200 mg/kg curcumin (200-cur) groups. …”
  16. 356

    S1 Fig - by Xinyue Yang (629144)

    Published 2024
    “…Sprague-Dawley (SD) rats were randomly divided into four groups: normal saline (NS), and 50 (50-cur), 100 (100-cur), and 200 mg/kg curcumin (200-cur) groups. …”
  17. 357

    S1 Data - by Xinyue Yang (629144)

    Published 2024
    “…Sprague-Dawley (SD) rats were randomly divided into four groups: normal saline (NS), and 50 (50-cur), 100 (100-cur), and 200 mg/kg curcumin (200-cur) groups. …”
  18. 358

    S5 Fig - by Xinyue Yang (629144)

    Published 2024
    “…Sprague-Dawley (SD) rats were randomly divided into four groups: normal saline (NS), and 50 (50-cur), 100 (100-cur), and 200 mg/kg curcumin (200-cur) groups. …”
  19. 359

    S4 Fig - by Xinyue Yang (629144)

    Published 2024
    “…Sprague-Dawley (SD) rats were randomly divided into four groups: normal saline (NS), and 50 (50-cur), 100 (100-cur), and 200 mg/kg curcumin (200-cur) groups. …”
  20. 360

    S3 Fig - by Xinyue Yang (629144)

    Published 2024
    “…Sprague-Dawley (SD) rats were randomly divided into four groups: normal saline (NS), and 50 (50-cur), 100 (100-cur), and 200 mg/kg curcumin (200-cur) groups. …”